These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 33744715)

  • 1. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.
    Rosati G; Lonardi S; Galli F; Di Bartolomeo M; Ronzoni M; Zampino MG; Banzi M; Zaniboni A; Pasini F; Bozzarelli S; Garattini SK; Ferrari D; Montesarchio V; Mambrini A; Ciuffreda L; Galli F; Pusceddu V; Carlomagno C; Bidoli P; Amoroso D; Bochicchio AM; Frassineti L; Corsi D; Bilancia D; Pastorino A; De Stefano A; Labianca R;
    Eur J Cancer; 2021 May; 148():190-201. PubMed ID: 33744715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.
    Gallois C; Shi Q; Pederson LD; André T; Iveson TJ; Sobrero AF; Alberts S; de Gramont A; Meyerhardt JA; George T; Schmoll HE; Souglakos I; Harkin A; Labianca R; Sinicrope FA; Oki E; Shields AF; Boukovinas I; Kerr R; Lonardi S; Yothers G; Yoshino T; Goldberg RM; Taieb J; Papamichael D
    J Clin Oncol; 2024 Jul; 42(19):2295-2305. PubMed ID: 38547438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
    André T; Meyerhardt J; Iveson T; Sobrero A; Yoshino T; Souglakos I; Grothey A; Niedzwiecki D; Saunders M; Labianca R; Yamanaka T; Boukovinas I; Vernerey D; Meyers J; Harkin A; Torri V; Oki E; Georgoulias V; Taieb J; Shields A; Shi Q
    Lancet Oncol; 2020 Dec; 21(12):1620-1629. PubMed ID: 33271092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
    Grothey A; Sobrero AF; Shields AF; Yoshino T; Paul J; Taieb J; Souglakos J; Shi Q; Kerr R; Labianca R; Meyerhardt JA; Vernerey D; Yamanaka T; Boukovinas I; Meyers JP; Renfro LA; Niedzwiecki D; Watanabe T; Torri V; Saunders M; Sargent DJ; Andre T; Iveson T
    N Engl J Med; 2018 Mar; 378(13):1177-1188. PubMed ID: 29590544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes associated with completion of adjuvant oxaliplatin-based chemotherapy for stage III colon cancer: A national population-based study.
    Boyle JM; Kuryba A; Cowling TE; van der Meulen J; Fearnhead NS; Walker K; Braun MS; Aggarwal A
    Int J Cancer; 2022 Jan; 150(2):335-346. PubMed ID: 34520572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
    Sobrero A; Lonardi S; Rosati G; Di Bartolomeo M; Ronzoni M; Pella N; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Zagonel V; Maiello E; Barni S; Rulli E; Labianca R;
    J Clin Oncol; 2018 May; 36(15):1478-1485. PubMed ID: 29620994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer: The ACHIEVE Phase 3 Randomized Clinical Trial.
    Yoshino T; Yamanaka T; Oki E; Kotaka M; Manaka D; Eto T; Hasegawa J; Takagane A; Nakamura M; Kato T; Munemoto Y; Takeuchi S; Bando H; Taniguchi H; Gamoh M; Shiozawa M; Mizushima T; Saji S; Maehara Y; Ohtsu A; Mori M
    JAMA Oncol; 2019 Nov; 5(11):1574-1581. PubMed ID: 31513248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study).
    Nakayama G; Takano N; Taniguchi H; Ishigure K; Yokoyama H; Teramoto H; Hashimoto R; Sakai M; Ishiyama A; Kinoshita T; Hayashi N; Nakamura M; Hattori N; Sato Y; Umeda S; Uehara K; Aiba T; Sonohara F; Hayashi M; Kanda M; Kobayashi D; Tanaka C; Yamada S; Koike M; Fujiwara M; Murotani K; Ando M; Ando Y; Muro K; Kodera Y
    Eur J Cancer; 2021 Feb; 144():61-71. PubMed ID: 33340853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.
    Tournigand C; André T; Bonnetain F; Chibaudel B; Lledo G; Hickish T; Tabernero J; Boni C; Bachet JB; Teixeira L; de Gramont A
    J Clin Oncol; 2012 Sep; 30(27):3353-60. PubMed ID: 22915656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
    Gallois C; Taieb J; Le Corre D; Le Malicot K; Tabernero J; Mulot C; Seitz JF; Aparicio T; Folprecht G; Lepage C; Mini E; Van Laethem JL; Emile JF; Laurent-Puig P;
    Clin Cancer Res; 2018 Oct; 24(19):4745-4753. PubMed ID: 29921730
    [No Abstract]   [Full Text] [Related]  

  • 13. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.
    Nakamura Y; Yamanaka T; Chin K; Cho H; Katai H; Terashima M; Misawa K; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Bando H; Kawashima Y; Fukunaga T; Gotoh M; Ishibashi T; Shitara K
    Ann Surg Oncol; 2019 Feb; 26(2):465-472. PubMed ID: 30456678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
    Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
    JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.
    Rosati G; Galli F; Cantore M; Bergamo F; Banzi M; Zampino MG; Mattioli R; Cardellino GG; Ronzoni M; Di Bartolomeo M; Tamberi S; Marchetti P; Rimassa L; Corsi D; Bochicchio AM; Artioli F; Labianca R; Galli F; Rulli E; Bilancia D; Bregni G;
    Oncologist; 2020 Jun; 25(6):e928-e935. PubMed ID: 31943506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.
    Sinicrope FA; Chakrabarti S; Laurent-Puig P; Huebner L; Smyrk TC; Tabernero J; Mini E; Goldberg RM; Zaanan A; Folprecht G; Van Laethem JL; Le Malicot K; Shi Q; Alberts SR; Taieb J
    Eur J Cancer; 2021 Feb; 144():101-112. PubMed ID: 33341444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
    de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
    Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project.
    Souglakos J; Boukovinas I; Kakolyris S; Xynogalos S; Ziras N; Athanasiadis A; Androulakis N; Christopoulou A; Vaslamatzis M; Ardavanis A; Emmanouilides C; Bompolaki I; Kourousis C; Makrantonakis P; Christofyllakis C; Athanasiadis E; Kentepozidis N; Karampeazis A; Katopodi U; Anagnosopoulos A; Papadopoulos G; Prinarakis E; Kalisperi A; Mavroudis D; Georgoulias V
    Ann Oncol; 2019 Aug; 30(8):1304-1310. PubMed ID: 31228203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
    Lonardi S; Sobrero A; Rosati G; Di Bartolomeo M; Ronzoni M; Aprile G; Massida B; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Barni S; Zagonel V; Maiello E; Rulli E; Labianca R;
    Ann Oncol; 2016 Nov; 27(11):2074-2081. PubMed ID: 27573560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.